This cross-sectional study evaluates the cost per event averted in adjuvant cancer trials between January 2018 and March 2022. Click to show full abstract
This cross-sectional study evaluates the cost per event averted in adjuvant cancer trials between January 2018 and March 2022.
               
Click one of the above tabs to view related content.